
Opinion|Videos|November 4, 2024
Protocol Development for Administration and AE Management of Bispecifics
Panelists discuss how they developed their protocols for administering bispecific antibodies and monitoring and managing associated adverse events.
Advertisement
Video content above is prompted by the following:
How did you develop your administration and adverse event monitoring and management protocols?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Relacorilant Demonstrates Significant OS in Platinum-Resistant Ovarian Cancer
2
Oncologists Weigh BTK/BCL2 Inhibitor Combinations in CLL
3
FDA OKs Guardant360 CDx for Encorafenib Combo in BRAF V600E+ Metastatic CRC
4
Later-Line and Combination Therapies in cGVHD and Future Directions
5


















